Oppenheimer Asset Management Inc. Acquires 4,125 Shares of Edwards Lifesciences Corporation (NYSE:EW)

Oppenheimer Asset Management Inc. boosted its position in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 23.5% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 21,699 shares of the medical research company's stock after acquiring an additional 4,125 shares during the quarter. Oppenheimer Asset Management Inc.'s holdings in Edwards Lifesciences were worth $1,573,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in EW. Vanguard Group Inc. lifted its holdings in shares of Edwards Lifesciences by 10.4% in the fourth quarter. Vanguard Group Inc. now owns 69,132,036 shares of the medical research company's stock worth $5,117,845,000 after acquiring an additional 6,537,494 shares during the last quarter. Wellington Management Group LLP increased its position in Edwards Lifesciences by 5.3% during the 4th quarter. Wellington Management Group LLP now owns 33,210,879 shares of the medical research company's stock worth $2,458,601,000 after purchasing an additional 1,678,154 shares in the last quarter. Geode Capital Management LLC lifted its stake in Edwards Lifesciences by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 13,647,341 shares of the medical research company's stock valued at $1,007,520,000 after purchasing an additional 126,194 shares during the last quarter. Fisher Asset Management LLC boosted its position in Edwards Lifesciences by 7.7% in the fourth quarter. Fisher Asset Management LLC now owns 9,775,276 shares of the medical research company's stock valued at $723,664,000 after buying an additional 696,965 shares in the last quarter. Finally, Norges Bank acquired a new stake in Edwards Lifesciences in the fourth quarter valued at approximately $610,895,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Trading Up 1.2%

Shares of NYSE:EW traded up $0.92 during midday trading on Friday, reaching $78.07. The company's stock had a trading volume of 6,205,587 shares, compared to its average volume of 5,242,644. Edwards Lifesciences Corporation has a fifty-two week low of $58.93 and a fifty-two week high of $95.25. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.66 and a current ratio of 4.45. The firm has a 50 day moving average price of $75.62 and a two-hundred day moving average price of $73.15. The firm has a market capitalization of $45.80 billion, a price-to-earnings ratio of 11.15, a PEG ratio of 3.94 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its earnings results on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share for the quarter, topping analysts' consensus estimates of $0.60 by $0.04. The business had revenue of $1.41 billion during the quarter, compared to the consensus estimate of $1.40 billion. Edwards Lifesciences had a return on equity of 16.62% and a net margin of 75.48%. The firm's revenue for the quarter was up 6.2% on a year-over-year basis. During the same period in the previous year, the company posted $0.66 earnings per share. As a group, analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on EW. Wall Street Zen cut Edwards Lifesciences from a "buy" rating to a "hold" rating in a research note on Friday, May 16th. Truist Financial dropped their target price on Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating for the company in a research report on Friday, April 11th. Piper Sandler lifted their price target on Edwards Lifesciences from $80.00 to $83.00 and gave the company an "overweight" rating in a research note on Tuesday, May 13th. Citigroup reaffirmed a "buy" rating and issued a $95.00 price objective (up previously from $84.00) on shares of Edwards Lifesciences in a research note on Thursday, May 22nd. Finally, Robert W. Baird lifted their target price on shares of Edwards Lifesciences from $72.00 to $75.00 and gave the stock a "neutral" rating in a research report on Thursday, April 24th. One investment analyst has rated the stock with a sell rating, fourteen have given a hold rating and eleven have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $80.20.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, insider Larry L. Wood sold 8,950 shares of Edwards Lifesciences stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $75.23, for a total transaction of $673,308.50. Following the completion of the transaction, the insider now owns 206,900 shares in the company, valued at approximately $15,565,087. The trade was a 4.15% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Donald E. Bobo, Jr. sold 9,500 shares of the business's stock in a transaction that occurred on Monday, April 14th. The stock was sold at an average price of $69.81, for a total value of $663,195.00. Following the sale, the vice president now directly owns 47,206 shares of the company's stock, valued at $3,295,450.86. This represents a 16.75% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 40,648 shares of company stock valued at $2,998,866 in the last three months. Corporate insiders own 1.29% of the company's stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.